A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting
Status:
Withdrawn
Trial end date:
2016-06-29
Target enrollment:
Participant gender:
Summary
This multi-center, single-arm study is designed to evaluate clinical experience of
participants (or caregivers) administering lebrikizumab at home in participants with asthma.
Eligible participants will receive four doses of subcutaneous (SC) lebrikizumab every 4 weeks
(q4w) up to Week 12. Primary analysis visit occurs at Week 13. After study treatment, all
participants will complete a 12 week safety follow up. All participants will get training for
the administartion of lebrikizumab using the device.